

Amisha V Barochia

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5914177/amisha-v-barochia-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

15
papers

1,194
citations

10
h-index

15
g-index

15
ext. papers

1,392
ext. citations

6.3
avg, IF

3.72
L-index

#	Paper	IF	Citations
15	Reply: All HDL particles are not equal in IPF.. <i>European Respiratory Journal</i> , 2022 ,	13.6	
14	Use of Fractional Exhaled Nitric Oxide to Guide the Treatment of Asthma: An Official American Thoracic Society Clinical Practice Guideline. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, e97-e109	10.2	7
13	Serum levels of small HDL particles are negatively correlated with death or lung transplantation in an observational study of idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , 2021 , 58,	13.6	3
12	High density lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics. <i>Journal of Lipid Research</i> , 2017 , 58, 1713-1721	6.3	15
11	High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease. <i>Frontiers in Pharmacology</i> , 2016 , 7, 323	5.6	53
10	Emerging Roles of Apolipoprotein E and Apolipoprotein A-I in the Pathogenesis and Treatment of Lung Disease. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016 , 55, 159-69	5.7	67
9	Serum apolipoprotein A-I and large high-density lipoprotein particles are positively correlated with FEV1 in atopic asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, 990-1000	10.2	47
8	Raxibacumab augments hemodynamic support and improves outcomes during shock with B. anthracis edema toxin alone or together with lethal toxin in canines. <i>Intensive Care Medicine Experimental</i> , 2015 , 3, 9	3.7	7
7	The Surviving Sepsis Campaign's Revised Sepsis Bundles. <i>Current Infectious Disease Reports</i> , 2013 , 15, 385-93	3.9	17
6	Protective antigen antibody augments hemodynamic support in anthrax lethal toxin shock in canines. <i>Journal of Infectious Diseases</i> , 2012 , 205, 818-29	7	13
5	Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011 , 7, 479-94	5.5	118
4	The evolving experience with therapeutic TNF inhibition in sepsis: considering the potential influence of risk of death. <i>Expert Opinion on Investigational Drugs</i> , 2011 , 20, 1555-64	5.9	68
3	Bundled care for septic shock: an analysis of clinical trials. <i>Critical Care Medicine</i> , 2010 , 38, 668-78	1.4	754
2	Risk of death and the efficacy of eritoran tetrasodium (E5564): design considerations for clinical trials of anti-inflammatory agents in sepsis. <i>Critical Care Medicine</i> , 2010 , 38, 306-8	1.4	18
1	Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies. <i>Biologics: Targets and Therapy</i> , 2009 , 3, 391-406	4.4	7